Albumin in Acute Variceal Bleeding
Key facts
- Phase
- Phase 3
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07395141, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- King George's Medical University
- Trial code
- NCT07395141
- Record updated
- 9 February 2026
- Original description
The objective of this randomized control clinical trial is to learn the role of albumin in patients with acute variceal bleed. The trial will include all adult patients with acute variceal bleeding and cirrhosis presenting to Medical Gastroenterology department at KGMU, Lucknow, U.P. India, will include patients with age between 18-70 years and all gender.Read full original descriptionShow less
Albumin in Acute Variceal Bleeding: A Randomized Controlled Trial: ALB-AVB Trial
The objective of this randomized control clinical trial is to learn the role of albumin in patients with acute variceal bleed. The trial will include all adult patients with acute variceal bleeding and cirrhosis presenting to Medical Gastroenterology department at KGMU, Lucknow, U.P. India, will include patients with age between 18-70 years and all gender.
The primary endpoint will be re-bleeding during hospitalization and at 6 weeks. Participants will be randomized in two groups, the intervention group will receive albumin for 3 days along with standard treatment and comparison group will receive on standard treatment.
Inclusion: All adult patients with acute variceal bleeding and cirrhosis presenting to Medical Gastroenterology department at KGMU, Lucknow, U.P. India.
Exclusion: Patients with portal vein thrombosis; Extrahepatic portal vein thrombosis; Patients with heart failure; Patients with chronic kidney disease; Patients who received albumin in the last one month; Age < 18 years and > 70 years; Hepatocellular carcinoma; Non-cirrhotic portal fibrosis; Patients who require fresh frozen plasma; Volume overload state.